Global Pasireotide Drugs Market Size By Type (0.3mg/ml, 0.6mg/ml), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Pasireotide Drugs Market was valued at USD 410 million in 2023 and is projected to reach USD 762 million by 2031, growing at a CAGR of 7.9% during the forecast period of 2023 to 2031. Pasireotide, a somatostatin analog, is primarily used in treating Cushing’s disease and acromegaly. The market growth is driven by rising incidences of pituitary tumors, increased awareness about endocrine disorders, and the expanding pipeline of long-acting formulations. With advancements in targeted therapy and supportive regulatory frameworks, pasireotide drugs are gaining traction globally.

Drivers:

1. Increasing Prevalence of Cushing’s Disease and Acromegaly

The growing incidence of rare endocrine disorders like Cushing’s disease and acromegaly has led to heightened demand for effective therapies. Pasireotide, as a first-in-class drug approved for these conditions, is witnessing increased uptake.

2. Favorable Regulatory Support

The designation of pasireotide as an orphan drug by regulatory authorities like the FDA and EMA is expediting its market approval timelines and incentivizing pharmaceutical investments.

3. Advancements in Drug Delivery Systems

Continuous innovations, such as the development of long-acting injectable formulations, are enhancing treatment adherence and improving patient outcomes, thereby boosting market penetration.

Restraints:

1. High Cost of Therapy

The high price point of pasireotide, particularly for long-term use in chronic conditions, can limit its adoption, especially in cost-sensitive and low-income regions.

2. Side Effects and Contraindications

Pasireotide is associated with side effects such as hyperglycemia, bradycardia, and gastrointestinal disturbances, which may limit its use among patients with comorbid conditions.

Opportunity:

1. Expansion into Emerging Markets

As healthcare infrastructure improves across Latin America, Asia-Pacific, and the Middle East, untapped markets with growing awareness and diagnostic capabilities offer significant growth potential for pasireotide drugs.

2. Development of Combination Therapies

Ongoing research into combining pasireotide with other pharmacological agents to enhance efficacy and reduce side effects presents new avenues for market players.

Market by System Type Insights:

Based on system type, long-acting release (LAR) formulations dominate the market. These offer the benefit of monthly administration, improving compliance for chronic disease management. The short-acting subcutaneous formulation, although still in use, is being phased out in favor of more convenient long-acting options.

Market by End-use Insights:

The hospital pharmacies segment led the market in 2023 due to the controlled and specialist administration requirements of pasireotide. Specialty clinics are also emerging as a key end-use segment, reflecting the trend toward decentralized, outpatient endocrine care for rare disease management.

Market by Regional Insights:

North America held the largest share of the pasireotide drugs market in 2023, driven by higher diagnosis rates, favorable reimbursement policies, and strong presence of key pharmaceutical companies. However, Asia-Pacific is expected to witness the fastest growth, fueled by increasing healthcare spending and awareness about pituitary disorders in countries like China and India.

Competitive Scenario:

Key players in the Global Pasireotide Drugs Market include:

Recordati S.p.A.

Novartis AG

Pfizer Inc.

Ipsen Biopharmaceuticals

Chiasma, Inc.

These companies are investing in clinical trials, regulatory approvals, and strategic partnerships to enhance their market footprint. For instance:

In 2023, Recordati launched an extended-release formulation of pasireotide in Europe.

Novartis expanded access programs in Latin America to increase drug affordability.

Scope of Work – Global Pasireotide Drugs Market

Key Market Developments:

October 2023: Novartis announced a Phase III trial evaluating pasireotide in combination with metyrapone for enhanced Cushing’s disease management.

June 2024: Recordati secured regulatory approval for pasireotide LAR in Australia, expanding its APAC footprint.

March 2025: Pfizer initiated preclinical research on novel pasireotide analogs with fewer metabolic side effects.

FAQs:

1) What is the current market size of the Global Pasireotide Drugs Market?

The market size was valued at USD 410 million in 2023.

2) What is the major growth driver of the Global Pasireotide Drugs Market?

The rising prevalence of endocrine disorders such as Cushing’s disease and acromegaly is the major growth driver.

3) Which is the largest region during the forecast period in the Global Pasireotide Drugs Market?

North America is expected to remain the largest regional market through the forecast period.

4) Which segment accounted for the largest market share in the Global Pasireotide Drugs Market?

The long-acting release (LAR) system type segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Pasireotide Drugs Market?

Key players include Recordati S.p.A., Novartis AG, Pfizer Inc., Ipsen Biopharmaceuticals, and Chiasma, Inc.